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Background: Pompe disease is a proximal myopathy. We investigated whether exercise training is a safe and useful
adjuvant therapy for adult Pompe patients, receiving enzyme replacement therapy.
Methods: Training comprised 36 sessions of standardized aerobic, resistance and core stability exercises over
12 weeks. Before and after, the primary outcome measures safety, endurance (aerobic exercise capacity and
distance walked on the 6 min walk test) and muscle strength, and secondary outcome measures core stability,
muscle function and body composition, were evaluated.
Results: Of 25 patients enrolled, 23 successfully completed the training. Improvements in endurance were shown
by increases in maximum workload capacity (110 W before to 122 W after training, [95 % CI of the difference 6 · 0
to 19 · 7]), maximal oxygen uptake capacity (69 · 4 % and 75 · 9 % of normal, [2 · 5 to 10 · 4]), and maximum walking
distance (6 min walk test: 492 meters and 508, [−4 · 4 to 27 · 7] ). There were increases in muscle strength of the hip
flexors (156 · 4 N to 180 · 7 N [1 · 6 to 13 · 6) and shoulder abductors (143 · 1 N to 150 · 7 N [13 · 2 to 35 · 2]). As an
important finding in secondary outcome measures the number of patients who were able to perform the core
stability exercises rose, as did the core stability balancing time (p < 0.05, for all four exercises). Functional tests
showed small reductions in the time needed to climb four steps (2 · 4 sec to 2 · 1, [− 0 · 54 to −0 · 04 ]) and rise to
standing position (5 · 8 sec to 4 · 8, [−2 · 0 to 0 · 0]), while time to run, the quick motor function test results and body
composition remained unchanged.
Conclusions: Our study shows that a combination of aerobic, strength and core stability exercises is feasible, safe
and beneficial to adults with Pompe disease.
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Pompe disease (glycogen storage disease type II, acid
maltase deficiency) (OMIM # 232300) is a rare meta-
bolic myopathy caused by glycogen accumulation result-
ing from deficiency of lysosomal acid α-glucosidase
(GAA). It presents as a wide clinical spectrum, the most* Correspondence: a.vanderploeg@erasmusmc.nl
1Center for Lysosomal and Metabolic Diseases, Department of Pediatrics,
Erasmus MC University Medical Center – Sophia Children’s Hospital, PO Box
2040, 3000, CA, Rotterdam, The Netherlands
Full list of author information is available at the end of the article
© 2015 van den Berg et al. This is an Open Ac
License (http://creativecommons.org/licenses/
medium, provided the original work is proper
creativecommons.org/publicdomain/zero/1.0/prominent symptoms in adults being proximal skeletal
muscle weakness and respiratory problems [1, 2]. Skel-
etal muscle weakness typically fits a pattern of limb-
girdle myopathy, with the abdominal and paraspinal
muscles and the musculature of the hip being the most
affected muscle groups [3–5].
Enzyme replacement therapy (ERT) with recombinant
human acid α-glucosidase (Myozyme/Lumizyme) was
approved for the treatment of Pompe disease in 2006. In
adults, ERT has been shown to elicit positive effects on
skeletal muscle strength, walking distance, respiratorycess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
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functioning may be further supported by treatments
additional to ERT, such as exercise training. Although
some recent studies suggest that exercise training may
be beneficial, evidence is still limited [9, 10].
A recent study on common clinical practice in the
Netherlands showed that there is a lack of uniformity
in the type of physical therapy training programs
applied, and that physical therapists and patients all
seek guidance and standardization [11]. We therefore
aimed to determine whether a standardized and well-
structured exercise intervention program combining
aerobic, resistance and core stability exercises was
feasible and safe, and whether it added value to treat-
ment with ERT alone. In a group of relatively mildly af-
fected adult Pompe patients receiving ERT for more
than a year, we evaluated the effects of such a regime
on endurance, muscle strength and function, core sta-
bility, and body composition.
Methods
Patients
Patients were recruited at the Centre for Lysosomal and
Metabolic Diseases, Erasmus MC University Medical
Centre, Rotterdam, the Dutch national referral centre
for patients with Pompe disease.
There were three inclusion criteria:
1. A confirmed diagnosis of Pompe disease measured
by decreased acid α-glucosidase activity in leuko-
cytes or fibroblasts, and mutation analysis;
2. Age > 17 years;
3. Treatment with ERT for at least 52 weeks
There were four exclusion criteria:
1. The use of walking-aids or a wheelchair;
2. Ventilator-dependency;
3. Concurrent medical conditions;
4. Participation in other exercise-training programs.
The study was approved by the Ethical Committee at
Erasmus MC University Medical Centre. Informed con-
sent was obtained from all patients.
Study design and intervention
Three times a week for 12 weeks, all patients followed a
standardized training program that was provided under
the supervision of physical therapists at carefully se-
lected sports or fitness centres near the patients’ homes.
To ensure the uniformity of the program and its super-
vision, all therapists attended a one-day instruction pro-
gram at Erasmus MC University Medical Centre. The
training program is depicted in Fig. 1. The first trainingsession was on-site supervised by one of the researchers
from Erasmus MC (LvdB, MF), who subsequently
attended each training site every two weeks to monitor
proper conduct of the program.
Patients were randomly subdivided into two groups:
group 1 (n = 13), which started the training program at
week 1; and group 2 (n = 12), which started at week 13.
The staggered start of training allowed us to investigate
whether any improvement observed in the training
period could also be attributed to ERT. Furthermore, the
duration of the effect of the training program can be
evaluated from the follow-up of patients in group 1 after
they stop training in week 12.
To assess the effects of the program, each patient visited
our centre (Erasmus MC) on two separate days in weeks 0,
12 and 24. The primary endpoints of this study were safety,
endurance and muscle strength. Secondary endpoints were
core stability, muscle function, and body composition.
Under the supervision of the physical therapist, train-
ing diaries were kept by all patients, who recorded the
days on which they trained, the weight and number of
repeats of resistance exercises, and the perceived level of
exertion. To evaluate training progress and patients’ mo-
tivation, patients were telephoned weekly.
Assessments
Safety
Plasma CK was measured every two weeks as a safety
marker for exercise-induced muscle damage [12], and
patients were contacted every week to record potential
side effects such as pain and fatigue.
Endurance
Aerobic (endurance) exercise capacity was determined
using an incremental cycle ergometer. After 4 min of
unloaded cycling on the cycloergometer (Jaeger ER 800;
Erich Jaeger, Würzburg Germany) exercise intensity was
increased progressively until exhaustion (i.e. ramp
protocol), during continuous measurement of patients’
heart rates and ventilator parameters using spiroergo-
metry equipment (Oxycon Pro, Jaeger, Würzburg,
Germany). The rate of increase was determined consider-
ing the patient’s functional capacities and ranged from 5–
20 Watts/minute. The duration of every individual test
exceeded 6 min but did not take longer than 12 min. At
exhaustion, the rating of exertional symptoms was
assessed using the Borg scale (scale 6–20) [13], patients
consistently scoring 14 or above. Maximum workload cap-
acity (WMAX) and, peak oxygen uptake capacity (VO2
PEAK) were measured. The ventilatory threshold (VT) was
assessed independently by two clinical exercise physiolo-
gists using the ventilatory equivalents method [14]. The
test was considered to be maximal when one of the fol-
lowing criteria was met [14]:
Fig. 1 Flowchart for the standardized exercise-training regime combining aerobic, resistance and core stability exercises
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2. respiratory exchange ratio (RER) > 1 · 11, or
3. VO2 stabilized despite increased workload.
Walking distance on the 6-min walk test (6MWT) was
evaluated according to the American Thoracic Society
guidelines.
Core Stability
To assess the dynamic balance, which reflects core sta-
bility, one physical therapist (MF) measured time in bal-
ance (in seconds) for each of the four core stability
exercises of the training program (Fig. 1) [15].
Muscle strength
Muscle strength was assessed by one investigator (SW)
using Hand-held Dynamometry (HHD). Assessments
were performed in a standardized manner, and sum
scores were calculated as described previously [6].
Muscle Function
Functional activity assessments comprised three timed
tests: 10 meter running, climbing four steps, and rising
from supine to standing positions [16], and the Quick
Motor Function Test (QMFT), a test specifically de-
signed and validated for Pompe patients [17]. The
QMFT consists of 16 specific motor skills related to
daily activities. A total score is achieved by summing the
scores for each item (ranging from 0 “cannot perform”
to 4 “can perform with no effort”), and is expressed as a
percentage of the maximum score.
Body composition
Bone-mineral density (BMD) and body-composition
measurements were performed conform DXA technol-
ogy using a Lunar DPX densitometer and analyzed with
Encore 2002 software (GE Lunar DPX, GE Health Care).
Bone densitometry was performed in a standardized
manner as described previously [18]. Body composition
was described in terms of the mineral, lean and fat body
mass (kilograms). The percentage of fat mass and, more
specifically, android and gynoid fat, were calculated.
Statistical analysis
Patient characteristics were summarized using descriptive
statistics. Data for the two groups were combined after
verifying that there were no significant differences be-
tween outcome measures before the start of the training
(group 1 – week 0; group 2 – week 12; student’s t-test for
normally distributed, and Mann–Whitney for not-
normally distributed data).
Mean differences before and after the training were
compared using the paired t-test for normally distributed
data, and otherwise the Wilcoxon signed rank test forpaired samples. For group 2, we also used these tests to
compare the outcome measures before and after
12 weeks of ERT only (week 0 to 12).
Significance level was set at p < 0 · 05. Statistical analyses
were performed using SPSS for Windows (release 17 · 0;
SPSS, Inc., Chicago, IL).
Results
Patients
A total of 25 patients fulfilled the inclusion criteria and
chose to participate in this study. Two patients did not
complete the training program because they were insuffi-
ciently motivated. This left 23 patients, who successfully
completed the study. Their ages ranged from 20 to 71 years
(median of 46 years). They had been receiving ERT for 1 to
6 years with a median of 3 years (Table 1).
Effect of ERT only
During the 12 weeks before training started, patients in
group 2 (ERT only) underwent the same set of assessments
as in the 12 weeks of training (ERT plus training). This en-
abled us to use group 2 to compare the effects of ERT only
with the combined effects of ERT and training. During the
first 12 weeks of ERT only, we detected no significant im-
provements in the main outcome measures.
Effect of training
Patients in the two randomly assigned groups were com-
parable in terms of age, gender, disease duration, time
on ERT, number of training sessions completed, and
baseline test results. This allowed us to analyse the effect
of training in the total group of 23 patients.
Safety
During the first week of training, two patients had a high
plasma CK level (10125 U/l and 6149 U/l), and also ex-
perienced muscle pain and fatigue. Over the following
week, their CK-values dropped to their normal range, and
the fatigue and pain disappeared. Both patients continued
training. None of the other patients had pain, fatigue, or in-
creases in plasma CK levels during the study period.
Endurance
All patients were able to complete the incremental cycle
test without adverse events. One was excluded from the
analysis because he did not reach the required maximum
intensity defined in the method section. After 12 weeks
of training WMAX, VO2peak and VT improved signifi-
cantly (Table 2). VO2peak and VT increased both in abso-
lute values and adjusted for body weight or as a
percentage of normal values. The ratio VT/VO2peak did
not change, as both the numerator and the denominator
increased. There were no significant differences between
patients’ maximum heart rates before and after 12 weeks
Table 1 Patient characteristics
Group 1 (n = 12) Group 2 (n = 11) Total group (n = 23) P-value*
Male gender (%) 7 (58 %) 5 (45 %) 12 (52 %) 0.54
Age in years (range) 45.4 (19.6-70.5) 46.6 (32.9-66.1) 46.0 (19.6-70.5) 0.85
Disease duration in years (range) 15.5 (8.1-28.1) 16.1 (6.0-32.1) 15.8 (6.0-32.1) 0.83
ERT duration in years (range) 3.3 (1.4-6.5) 3.0 (1.3-3.6) 3.1 (1.3-6.5) 0.96
Training sessions (max. 36) 33 (27–36) 32 (24–35) 32 (24–36) 0.70
Group 1 trained in weeks 1–12 and Group 2 trained in weeks 13–24
ERT enzyme replacement therapy
*For the difference between group 1 and 2 (chi-2 test for proportions and Wilcoxon signed rank test for continuous data)
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on an increase in fitness rather than on greater exertions
by the patients towards the end of the training period.
FVC did not change. Average walking distance on the
6MWT increased by 16 meters ([4.4-27.7], p = 0.01).Table 2 Aerobic fitness measured in an incremental cycle test
and a 6-min walk test before and after 12 weeks of training
Before training After training P-value**
Mean ± SD Mean ± SD
Incremental cycle test
(N = 22a)
Ventilatory threshold (VT)
• Absolute values (l/min) 1.25 ± 0.36 1.38 ± 0.36 <0.01
• Adjusted for body weight
(ml/min/kg)
16.7 ± 4.3 18.5 ± 4.7 <0.01
• VT/VO2 peak (%) 77.6 ± 12.1 78.3 ± 12.3 0.742
Data at exhaustion
• Maximum workload
(Wmax, Watt)
110 ± 52 122 ± 53 <0.01
• Maximum heart rate
(bpm)
156 ± 25 161 ± 20 0.16
• Pulmonary ventilation
(l/min)
59.6 ± 20.2 68.2 ± 21.0 <0.01
• Tidal volume (l) 1.85 ± 0.48 1.85 ± 0.44 0.91
• Gas exchange ratio 1.15 ± 0.09 1.14 ± 0.08 0.71
Peak oxygen uptake
(VO2 peak)
• Absolute values(l/min) 1.67 ± 0.62 1.82 ± 0.60 <0.01
• Adjusted for body weight
(ml/min/kg)
22.1 ± 7.0 24.1 ± 7.1 <0.01
• As % of normal 69.4 ± 17.4 75.9 ± 18.0 <0.01
6-min walk test (N = 22)
• Maximum walking
distance (6MWT, m)
492 ± 89 508 ± 97 0.01
Pulmonary function test
(N = 23)
• Forced vital capacity
(FVC, % of normal)
89.2 ± 12.6 90.0 ± 14.0 0.51
** For the difference before and after training (paired samples t-test)
aOne patient was excluded because he did not reach the required
maximum intensityCore stability
Figure 2 shows the results of the core stability tests. At the
start of the program, many patients experienced difficulties
in performing the core stability exercises, reporting prob-
lems with initiating movement and controlling balance.
During the training program, the number of patients who
were able to perform the exercises increased for three of
the four exercises (from 17 to 21 for the abdominal bridge,
15 to 16 for the left side bridge and 13 to 16 for the right
side bridge). The average time they were able to remain in
balance improved for all four positions (by 58 % for the
back bridge, 229 % for the left and 223 % for the right side
bridges, and 86 % for the abdominal bridge; p < 0 · 05).
Muscle strength
Of the nine muscle groups tested, there were increases
in the strength of the hip flexors and shoulder abductors
(Table 3).
Muscle function
Twelve weeks of training significantly reduced the time
taken by patients to climb four steps (on average
0.3 sec less, [−0 · 54 to −0 · 04], p = 0.02 Table 4) and to
rise from supine to a standing position (1 sec less,
[−2.0 to0 · 01], p = 0.05). The QMFT sum score and the
time to run 10 meters did not change.
Body composition
There were no changes in mineral bone mass (2 · 83 kg ±
0 · 58 before training vs. 2 · 82 kg ± 0 · 57 after training), in
lean body mass (42 · 53 kg ± 7 · 99 vs. 43 · 14 kg ± 8 · 28), or
in fat mass (30 · 11 kg ± 9.23 vs. 29 · 29 kg ± 9 · 06). Like-
wise, there were no changes in bone mineral density, over-
all fat percentage, and android and gynoid fat percentages
(results not shown).
Duration of training effect
After the initial 12 weeks of training group 1 was planned
to discontinue training, but 11 of 13 patients chose to con-
tinue training with the same or slightly modified intensity.
Therefore we were not able to assess how long the training
effect maintained after withdrawal.
Fig. 2 Time patients (N = 23) were able to remain in balance for the four different core stability exercises before (white bars) and after training
(black bars)
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This study provides clinical evidence that a combination of
aerobic, resistance and core stability training can be per-
formed safely in patients with Pompe disease, and helps to
improve endurance, core stability and muscle function.
Improved endurance was shown by improved aerobic
fitness over 12 weeks of training. In addition to the 11 %
increase in maximum workload capacity, peak oxygen
uptake and ventilatory threshold improved by 9 % and
10 %, and the 6MWT by 3 %. The increase in peak oxy-
gen uptake was relatively small compared to a number
of studies in neuromuscular dystrophies and metabolic
myopathies like McArdle disease, showing an increase
ranging from 12-47 %. [19–22] In these studies, patients
spent more time per week on endurance training, whichTable 3 Muscle strength measured by hand-held dynamometry
(HHD) before and after 12 weeks of training
Before training After training P-value*
Mean ± SD Mean ± SD
HHD of individual muscle
groups (Newton) (N = 23)
• Neck extensors 142.1 ± 18.4 140.4 ± 13.8 0.65
• Neck flexors 124.7 ± 40.2 132.1 ± 33.9 0.09
• Shoulder abductors 143.1 ± 29.1 150.7 ± 35.4 0.02
• Elbow flexors 226.4 ± 41.5 230.8 ± 42.3 0.42
• Elbow extensors 180.5 ± 20.1 176.2 ± 25.3 0.27
• Hip flexors 156.4 ± 61.9 180.7 ± 57.7 <0.01
• Hip abductors 159.4 ± 58.3 158.0 ± 68.1 0.75
• Knee extensors 189.2 ± 34.1 193.0 ± 31.8 0.27
• Knee flexors 121.2 ± 57.2 122.6 ± 56.7 0.51
*For the difference before and after training (paired samples t-testmight explain the larger increase. A second explanation
might be the lower baseline VO2peak than in our study.
The baseline values on VO2peak we found in our study
were slightly higher than those reported in two Italian
studies of Pompe patients (range 15.1 – 26.4 ml/kg/min).
[23, 24] These include 8 patients who were assessed prior
to treatment (median 20.5 mg/kg/min), and one patient
assessed during ERT (15.7 mg/kg/min), while all our pa-
tients had been on ERT for at least a year, which might ex-
plain the somewhat higher VO2peak values in our cohort.
Nevertheless, our 6MWT results also suggest that our co-
hort had a relatively good endurance capacity before the
training (77 % of normal expected). Finally, their ventila-
tory threshold as a percentage of the peak oxygen uptake
(78 %) is relatively high for an untrained population, and
comparable to that seen in the three Italian patients that
reached the VT (five did not reach the VT in this study,Table 4 Muscle function measured by the quantitative motor
function test (QMFT) and timed tests before and after 12 weeks
of training
Before training After training P-value*
Mean ± SD Mean ± SD
QMFT score (N = 22b) 51 ± 8 51 ± 9 0.65
Timed Tests (N = 22b)
– 10 m running (sec) 4.97 ± 1.50 4.70 ± 1.34 0.16
– Climbing four steps
(sec)a
2.37 ± 0.80 2.08 ± 0.74 0.02
– Rising from supine
to standing position
(sec)a
5.83 ± 4.25 4.83 ± 2.38 0.05
*For the difference before and after training (paired samples t-test and the
Wilcoxon signed-ranks test for paired dataa)
bQMFT score and timed test were not available for one patient
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relatively good endurance and tolerance capacity before
training, which is in agreement with the fact that mildly
affected Pompe patients were selected for this study.
So far the 6MWT was used in clinical trials for Pompe
disease to assess endurance capacity, but since most pa-
tients have walking difficulties it has been questioned
whether the 6MWT fully reflects this [25, 26]. Our study
indicates that the incremental cycle test offers a good al-
ternative to test endurance capacity, providing insight
into patients’ aerobic capacity.
Core stability has not been trained previously in neuro-
muscular disorders presenting with limb-girdle weakness.
One possible reason may lie in the assumption that core
stability exercises are not feasible for such patients. In-
deed, on starting training, many patients had difficulty
performing the exercises. During the program, however,
they learned to activate the proper muscle groups and
were able to remain in balance for longer. Our results thus
indicate that core stability training is feasible and improves
time in balance in patients with Pompe disease who are
treated with ERT. Feedback from patients during the
training also suggests that they perceived their improved
core stability to facilitate daily activities. Further studies
on how training influences patient reported outcomes
such as quality of life are needed.
An increase in muscle strength was observed in two of
the nine muscle groups tested: the hip flexors and shoul-
der abductors. We are not completely certain whether
the increased strength of the hip flexors resulted from
strength training, core stability exercises, or both. Core
stability may support gains in muscle strength by im-
proving proprioception and coordination.
The combined effects of the training program on endur-
ance, core stability, and muscle strength also led to some
functional improvement, with patients becoming able to
climb four stairs and rise to a standing position faster.
In our study all patients received enzyme replacement
therapy. It has been reported that the main incremental ef-
fects of enzyme replacement therapy (ERT) are observed
during the first year. Therefore only patients who had re-
ceived ERT more than 1 year were allowed to participate.
The study had a staggered design with patients in group 2
starting after a period of no training allowing evaluation of
the effect of ERT only, and patients in group 1 scheduled to
stop training after 12 weeks with the intention to study
how long the effect of training continued. During ERT only
patients remained more or less stable indicating that train-
ing was the main driver behind the effects. We were not
able to assess how long the training effect continued, since
all patients in group 1, except two, chose to continue train-
ing after 12 weeks. Although patients’ choice interfered with
our study design, it also reflects the positive feedback they
have given us on the program.Compliance was high in our study. It is likely that the
beneficial effects experienced, the supervision by physio-
therapists and weekly telephone consultations contrib-
uted to this. We therefore recommend that the program
be incorporated into regular supervised physiotherapy
sessions.
Few studies have been conducted on exercise and
training in Pompe disease. The largest so far was per-
formed before ERT became available [9]. For a mean
duration of four years, 26 patients participated in a com-
bined nutrition and endurance exercise therapy program
that led to improved muscle function as measured with
the Walton score. More recently, a German observa-
tional study showed that the effect of ERT on walking
distance was most pronounced in five patients who, inci-
dentally, were also subjected to endurance training on a
cycle ergometer during ERT infusions [10]. Two other
studies, one in mice and one in five adult patients with
Pompe disease, however, did not confirm a beneficial ef-
fect of endurance training while receiving ERT [27, 28].
Previous exercise studies in Pompe disease mainly fo-
cused on endurance training. It has been envisaged that
resistance training might lead to muscle damage, thereby
aggravating muscle weakness [29–31]. Prior to our
study, only Terzis et al. [28] combined endurance with
resistance training in five patients with Pompe disease
receiving ERT. The combined results of these five pa-
tients showed that both muscular strength and walking
distance improved.
Before starting our study we carefully considered whether
we should perform exercise-endurance training only, or a
combination of different types of exercises. We chose the
latter, because we not only wanted to improve endurance,
but also target all affected muscles (resistance exercises),
and ameliorate proprioception and the strength of those
proximal muscles not targeted by resistance training (core
stability exercises). Our decision to use a combined pro-
gram was also driven by the fact that our patient population
was not large enough to run three separate programs.
Although we cannot rule out the possibility that en-
durance training alone might have had a greater impact
on endurance, we observed that the extra exercises had
positive effects on core stability, and may also have im-
proved muscle strength and function. Earlier studies in
patients with inherited muscular myopathies did not in-
clude core stability exercises; our study shows them to
be both safe and easy to learn. Patients in our study were
mildly affected; those who are more severely affected
may need slightly adjusted exercise-training programs
but we recommend to include similar components.
Conclusions
Our study shows that a combination of endurance,
strength and core stability training is feasible and can be
van den Berg et al. Orphanet Journal of Rare Diseases  (2015) 10:87 Page 8 of 8performed safely in patients with Pompe disease. Such
training helps to improve endurance, muscle strength,
muscle function and core stability. This training pro-
gram thus seems to offer added value for Pompe patients
to those of ERT.
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